Could a bone drug ease CRPS pain? large trial underway

NCT ID NCT07210515

Recruiting now Symptom relief Sponsor: Ambros Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 9 times

Summary

This phase 3 trial tests whether the drug neridronate, given as four IV infusions over 10 days, can reduce pain and other symptoms of complex regional pain syndrome type 1 (CRPS-1). About 270 adults with CRPS in one limb will receive either the drug or a placebo. The main goal is to see if pain levels drop more with neridronate after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Neridronate (a bisphosphonate drug given intravenously)
What this could lead to: If it works, this could provide a new treatment option to reduce pain and severity of CRPS type 1.
What could go wrong: This is a phase 3 trial, but previous results may not guarantee success. The drug may not outperform placebo, and side effects from IV infusions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complex regional pain syndrome complex regional pain syndrome type 1 Edema Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMPLEX REGIONAL PAIN SYNDROME TYPE I

Contacts and locations

Locations

Ambros Clinical Trial Site
RECRUITING

Phoenix, Arizona, 85032, United States
Ambros Clinical Trial Site
RECRUITING

Tucson, Arizona, 85710, United States
Ambros Clinical Trial Site
RECRUITING

Napa, California, 94558, United States
Ambros Clinical Trial Site
RECRUITING

Pasadena, California, 91105, United States
Ambros Clinical Trial Site
RECRUITING

Tustin, California, 92780, United States
Ambros Clinical Trial Site
RECRUITING

Washington D.C., District of Columbia, 20006, United States
Ambros Clinical Trial Site
RECRUITING

Brandon, Florida, 33511, United States
Ambros Clinical Trial Site
RECRUITING

Daytona Beach, Florida, 32117, United States
Ambros Clinical Trial Site
RECRUITING

Pembroke Pines, Florida, 33025, United States
Ambros Clinical Trial Site
RECRUITING

Lawrenceville, Georgia, 30046, United States
Ambros Clinical Trial Site
RECRUITING

Newnan, Georgia, 30265, United States
Ambros Clinical Trial Site
RECRUITING

Chicago, Illinois, 60640, United States
Ambros Clinical Trial Site
RECRUITING

Orland Park, Illinois, 60462, United States
Ambros Clinical Trial Site
RECRUITING

Reno, Nevada, 89511, United States
Ambros Clinical Trial Site
RECRUITING

Shrewsbury, New Jersey, 07702, United States
Ambros Clinical Trial Site
RECRUITING

Charlotte, North Carolina, 28211, United States
Ambros Clinical Trial Site
RECRUITING

Wilmington, North Carolina, 28412, United States
Ambros Clinical Trial Site
RECRUITING

Winston-Salem, North Carolina, 27103, United States
Ambros Clinical Trial Site
RECRUITING

Dayton, Ohio, 45432, United States
Ambros Clinical Trial Site
RECRUITING

Fort Worth, Texas, 76244, United States
Ambros Clinical Trial Site
RECRUITING

Houston, Texas, 77079, United States
Ambros Clinical Trial Site
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.